Is Plasma Ac-SDKP Level a Reliable Marker of Chronic Angiotensin-Converting Enzyme Inhibition in Hypertensive Patients?
- 1 May 1998
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hypertension
- Vol. 31 (5), 1201-1202
- https://doi.org/10.1161/01.hyp.31.5.1201
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Angiotensin II stimulates proliferation of normal early erythroid progenitors.JCI Insight, 1997
- Effects of the angiotensin-converting enzyme inhibitor enalapril on blood haematopoietic progenitors and acetyl-N-Ser-Asp-Lys-Pro concentrations.European Journal of Clinical Investigation, 1997
- Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline.JCI Insight, 1996
- The Hemoregulatory Peptide N-Acetyl-Ser-Asp-Lys-Pro Is a Natural and Specific Substrate of the N-terminal Active Site of Human Angiotensin-converting EnzymeJournal of Biological Chemistry, 1995
- Direct and reversible inhibitory effect of the tetrapeptide acetyl-N- Ser-Asp-Lys-Pro (Seraspenide) on the growth of human CD34+ subpopulations in response to growth factorsBlood, 1993
- Calcium: its modulation in liver by cross-talk between the actions of glucagon and calcium-mobilizing agonistsBiochemical Journal, 1993
- Clinical Pharmacokinetics of Angiotensin Converting Enzyme (ACE) Inhibitors in Renal FailureClinical Pharmacokinetics, 1993
- Amelioration of Chemotherapy‐Induced Toxicity by Cotreatment with AcSDKP, a Tetrapeptide Inhibitor of Hematopoietic Stem Cell ProliferationAnnals of the New York Academy of Sciences, 1991
- Worsening of Anemia Induced by Long-Term Use of Captopril in Hemodialysis PatientsAmerican Journal of Nephrology, 1984